This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 High Growth Healthcare Stocks With Heavy Insider Buying

Are you looking to diversify with high growth stocks in the healthcare sector? The following stock list, which accounts for high earnings growth and internal management purchases could be a great way to jump start your search.

To create this list we started by screening the healthcare sector for companies that are expected to achieve high earnings growth going forward, with 5-year projected EPS growth above 15%.

Next, we looked for stocks with significant net insider purchases over the last six months representing over 1% of share float. Since insiders work at the companies in question, they have more knowledge about the firm than outsiders. Therefore, when they use their own money to purchase shares of their company's stock, it indicates they are bullish about the firm's future and believe current share price is undervalued. There are also studies that suggest when insider purchases greatly outweigh any insider selling, the stocks are correlated with outperformance in the market during the following six months.

Insiders think these healthcare stocks will live up their high growth expectations. Do you agree? 

‚ÄčAnalyze These Ideas: Getting Started: Access a performance overview for all stocks in the list

1. XOMA Corporation (XOMA) : Engages in the discovery, development, and manufacture of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. Market cap at $330.38M, most recent closing price at $4.0.

EPS growth over the next 5 years at 19%.

Over the last six months, insiders were net buyers of 4,722,670 shares, which represents about 9.8% of the company's 48.21M share float.
 

2. Genomic Health Inc. (GHDX): Focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Market cap at $1.03B, most recent closing price at $34.15.

EPS growth over the next 5 years at 32.95%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs